Kurt Huber

Showing 1-14 of 14 articles

Coronary interventions

Culprit lesion location and outcomes in patients with multi-vessel disease and infarct-related cardiogenic shock. A core laboratory analysis of the CULPRIT-SHOCK trial

Hauguel-Moreau M, Barthelemy O, Farhan s, Huber K, Rouanet S, Zeitouni M, Guedeney P, Hage G, Vicaut E, Zeymer U, Desch S, Thiele H, Montalescot G

September 8, 2020 | 10.4244/EIJ-D-20-00561

Coronary interventions

Angiographic predictors of outcome in myocardial infarction patients presenting with cardiogenic shock: A CULPRIT-SHOCK angiographic substudy

Overtchouk P, Barthelemy O, Hauguel-Moreau M, Guedeney P, Rouanet S, Zeitouni M, Silvain J, Collet J-P, Vicaut E, Zeymer U, Desch S, Thiele H, Montalescot G, Bertin B, Brugier D, Vignolles N, Hage G, El Kasty M, Kerneis M, Huber K, Sandri M, Noc M, Fuernau G

July 7, 2020 | 10.4244/EIJ-D-20-00139

EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic

Chieffo A, Stefanini G, Price S, Barbato E, Tarantini G, Karam N, Moreno R, Buchanan G, Gilard M, Halvorsen S, Huber K, James S, Neumann F, Möllmann H, Roffi M, Tavazzi G, Ferré J, Windecker S, Dudek D, Baumbach A

June 25, 2020 | 10.4244/EIJY20M05_01

Coronary interventions

Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes

Franzone A, McFadden E, Leonardi S, Piccolo R, Vranckx P, Serruys P, Hamm C, Steg P, Heg D, Branca M, Jüni P, Windecker S, Valgimigli M, Benit E, Janssens L, Ferrario M, Zurakowski A, Diletti R, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopczuk J, Liebetrau C

June 2, 2020 | 10.4244/EIJ-D-20-00145

Coronary interventions

Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial

Fabris E, van’t Hof A, Hamm C, Lapostolle F, Lassen J, Goodman S, ten Berg J, Bolognese L, Cequier A, Chettibi M, Hammett C, Huber K, Janzon M, Merkely B, Storey R, Zeymer U, Cantor W, Rousseau H, Vicaut E, Montalescot G

May 15, 2017 | 10.4244/EIJ-D-16-00965

Coronary interventions

Bivalirudin in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: uncertainties almost clarified

Huber K, Verheugt F

March 20, 2017 | 10.4244/EIJV12I16A315

Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement

Capodanno D, Lip G, Windecker S, Huber K, Kirchhof P, Boriani G, Lane D, Gilard M, Collet J-P, Valgimigli M, Byrne R

January 22, 2015 | 10.4244/EIJV10I9A174

Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force

Gorenek B, Blomström-Lundqvist C, Terradellas J, Camm A, Hindricks G, Huber K, Kirchhof P, Kuck K, Kudaiberdieva G, Lin T, Raviele A, Santini M, Tilz R, Valgimigli M, Vos M, Vrints C, Zeymer U, Kristiansen S

January 22, 2015

An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents

Katsaros K, Kastl S, Krychtiuk K, Hutter R, Zorn G, Maurer G, Huber K, Wojta J, Christ G, Speidl W

June 20, 2014 | 10.4244/EIJV10I2A36

Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care** and Thrombosis of the European Society of Cardiology

Hamon M, Pristipino C, Di Mario C, Nolan J, Ludwig J, Tubaro M, Sabate M, Mauri-Ferre J, Huber K, Niemela K, Haude M, Wijns W, Dudek D, Fajadet J, Kiemeneij F

March 22, 2013 | 10.4244/EIJV8I11A192

Time-related impact of distal embolisation on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation

De Luca G, Gibson C, Huber K, Dudek D, Cutlip D, Zeymer U, Gyöngyösi M, Bellandi F, Noc M, Arntz H-R, Maioli M, Secco G, Zorman S, Gabriel H, Emre A, Rakowski T, van’t Hof A

August 24, 2012 | 10.4244/EIJV8I4A74

Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update

Cuisset T, Valgimigli M, Mudra H, Mueller O, Wijns W, Huber K

May 25, 2010

Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions

Cuisset T, Mudra H, Mueller O, Vogt P, Angelillo-Scherrer A, Huber K

August 20, 2008

Gender-related outcome following percutaneous coronary intervention for ST-elevation myocardial infarction: data from the Austrian acute PCI registry

Suessenbacher A, Doerler J, Alber H, Aichinger J, Altenberger J, Benzer W, Christ G, Globits S, Huber K, Karnik R, Norman G, Siostrzonek P, Zenker G, Pachinger O, Weidinger F

August 20, 2008

1

Latest news

Special issue on PCR Valves e-Course; patient-centring the Heart Team, COVID and clinical trials...

Optimising the delivery of self-expanding valves according to vascular access

November 20, 2020

Fatal Acute Mesenteric Ischemia Following Transcatheter Aortic Valve Replacement

November 25, 2020

Patient preferences and Heart Team decision

November 20, 2020

Popular Tavi-A, TAILOR-PCI, ATPCI, PORTICO-IDE and more

(Thanks to the support of Biotronik)

November 12, 2020

Guidance Papers

Guidelines, consensus & position papers

August 28, 2020

Cardiovascular trials and COVID-19

Alexandra Lansky

November 25, 2020

This Week's JAA's: Win Ratio for Renal Denervation, Optimal strategy for NSTEMI in the very elderly, D-PUSH OCT Procedure...

November 24, 2020

Valvular disease